News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Holding AG Stops Enrolment into Avastin Trial
June 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss drugmaker Roche Holding AG has stopped enrolling patients into a late stage trial for Avastin and MabThera plus a type of chemotherapy in non-aggressive non-Hodgkin's Lymphoma, dealing the group a blow.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
MORE ON THIS TOPIC
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
·
3 min read
·
Annalee Armstrong
Obesity
Viking achieves ‘maintenance trifecta’ as GLP-1/GIP dual agonist exceeds expectations
September 22, 2026
·
3 min read
·
Heather McKenzie
Clinical research
Vertex opens up larger kidney disease opportunity with mid-stage readout
September 22, 2026
·
3 min read
·
Annalee Armstrong
Diabetes
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
September 22, 2026
·
2 min read
·
Annalee Armstrong
